First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? (Q38086355)

28 August 2017

First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? (English)

1 reference

28 August 2017

0 references

0 references

0 references

2

1 reference

PubMed ID

23458890

28 August 2017

Laurent Peyrin-Biroulet

series ordinal

1

object named as

Laurent Peyrin-Biroulet

1 reference

28 August 2017

4

Silvio Danese

1 reference

28 August 2017

Anthony Buisson

3

1 reference

PubMed ID

23458890

28 August 2017

language of work or name

English

0 references

publication date

5 March 2013

1 reference

Nature Reviews Gastroenterology & Hepatology

28 August 2017

1 reference

28 August 2017

10

1 reference

28 August 2017

6

1 reference

28 August 2017

345-351

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2013.31

28 August 2017

0 references

cites work

Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Development of the Crohn's disease digestive damage score, the Lémann score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

The natural history of adult Crohn's disease in population-based cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Review article: the natural history of postoperative Crohn's disease recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Impact of inflammatory bowel disease on health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Clinical implications of mucosal healing for the management of IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Surgery for adult Crohn's disease: what is the actual risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Adalimumab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Management of Crohn's disease in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Optimizing thiopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Clinical risk factors for complicated disease: how reliable are they?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Adalimumab safety in global clinical trials of patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Immunosuppression-related lymphomas and cancers in IBD: how can they be prevented?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

IBD: Mucosal healing--EXTENDing our knowledge in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Early Crohn disease: a proposed definition for use in disease-modification trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Infliximab for Crohn's disease: the first 500 patients followed up through 2009.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.31

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23458890

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRGASTRO.2013.31

1 reference

28 August 2017

1 reference

PubMed ID

23458890